In the LIGHTHOUSE study, Atsena Therapeutics is evaluating ATSN-201 gene therapy for X-linked retinoschisis, leveraging ...

Atsena Therapeutics, a clinical-stage gene therapy company focused on bringing the life-changing power of genetic medicine to reverse or prevent blindness, today announced dosing has been completed in ...

You’ll receive a dose of Keytruda every 3 or 6 weeks. Keytruda belongs to a class of biologic drugs called monoclonal antibodies. Specifically, it’s a type of monoclonal antibody called a PD-1 ...

“CRB-601 offers an intriguing upstream approach to modulating TGFβ signaling and this dose escalation study could yield valuable insights along with the potential to see the immune system being ...

And this was met by an arm we call modified titration. It met that primary objective and that ARIA-E frequency was 14% for ...

Suicide risk is not only elevated among individuals with psychiatric disorders, but also among individuals with medical conditions.